RxDoctor Payments DataLook up a doctor →

Melanie Greene, MD

Internal Medicine · Greenville, SCNPI 1922056647

Payments from drug & device makers

$141,824in general payments, 2019–2025

Across 228 payments — averaging $622.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$138K
  • Amgen$500
  • Lilly USA, LLC$399
  • Novo Nordisk$344
  • AbbVie$266
  • Novartis$227
  • plus $2K from 45 others

What the payments were for

  • Food & beverage$3,97499%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,824 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$235,048
Medicare patients
341
Services billed
11,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$179,665
MounjaroTirzepatide117$146,406
EliquisApixaban78$94,505
FarxigaDapagliflozin Propanediol57$73,785
JardianceEmpagliflozin23$30,711
Tresiba Flextouch U-200Insulin Degludec14$25,020
MyrbetriqMirabegron23$19,872
LinzessLinaclotide21$16,106
Repatha SureclickEvolocumab19$15,172
XareltoRivaroxaban14$12,091
JanuviaSitagliptin Phosphate12$6,812
SynthroidLevothyroxine Sodium70$6,104
Levothyroxine Sodium432$5,096
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$5,055
NexlizetBempedoic Acid/Ezetimibe11$4,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$344$179,665152 claims
Lilly USA, LLCMounjaro$399$146,406117 claims
PfizerEliquis$187$94,50578 claims
AstraZenecaFarxiga$91$73,78557 claims
Boehringer IngelheimJardiance$14$30,71123 claims
AbbVieLinzess, Synthroid$266$22,21091 claims
Astellas Pharma US IncMyrbetriq$143$19,87223 claims
MerckJanuvia$48$6,81212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$5,096432 claims
Esperion Therapeutics, Inc.Nexlizet$24$4,69611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →